EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	811	(514/235.2).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/11 11:22
L2	1129	(544/124).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/07/11 11:22
L3	114	l2 and l1	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/07/11 11:22

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:26:42 ON 11 JUL 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:27:11 ON 11 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JUL 2007 HIGHEST RN 942116-98-5
DICTIONARY FILE UPDATES: 10 JUL 2007 HIGHEST RN 942116-98-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10727168.str



chain nodes :
13 14 15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
3-13 6-7 10-15 11-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
3-13 7-8 7-12 8-9 9-10 10-11 10-15 11-12 11-14

exact bonds :
6-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:27:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11 TO 389
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 11:27:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 278 TO ITERATE

100.0% PROCESSED 278 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.01

L3 24 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.31

FILE 'CAPLUS' ENTERED AT 11:27:51 ON 11 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Jul 2007 VOL 147 ISS 3
FILE LAST UPDATED: 10 Jul 2007 (20070710/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:795716 CAPLUS
DOCUMENT NUMBER: 145:230638
TITLE: Preparation of [(2R,5S)-5-methyl-4-propylmorpholin-2-yl]pyridin-2-amine di-(S)-camphorsulfonate for treatment of sexual dysfunction and neurological disorders.
INVENTOR(S): Green, Stuart Peter; Lazzari, Olivier Alain; Miller, Duncan Charles; Salingue, Fabrice Henri
PATENT ASSIGNEE(S): Pfizer Limited, UK
SOURCE: PCT Int. Appl., 57pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082511	A1	20060810	WO 2006-IB222	20060126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
NL 1031087	A1	20060808	NL 2006-1031087	20060206
NL 1031087	C2	20070119		
US 2006183740	A1	20060817	US 2006-349324	20060206
PRIORITY APPLN. INFO.:			GB 2005-2509 A	20050207
			US 2005-654200P P	20050218

AB Title compound (I) was prepared I (preparation from 2-amino-5-bromopyridine, 2-chloro-N-methoxy-N-methylacetamide, (S)-2-amino-1-propanol, and propionaldehyde given) showed functional potency at the dopamine D3 receptor with EC50 = 21 nM.
IT 905577-05-1P 905577-06-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of methylpropylmorpholinylpyridinamine camphorsulfonate for treatment of sexual dysfunction and neurol. disorders)
RN 905577-05-1 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 5-[(2R,5S)-5-methyl-4-propyl-2-morpholinyl]-2-pyridinamine (2:1) (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



IT 905577-08-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of methylpropylmorpholinylpyridinamine camphorsulfonate for
treatment of sexual dysfunction and neurol. disorders)
RN 905577-08-4 CAPLUS
CN 2-Pyridinamine, 5-[(5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CM 1

CRN 710655-15-5
CMF C13 H21 N3 O

Absolute stereochemistry. Rotation (+).



CM 2

CRN 3144-16-9
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 905577-06-2 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 5-[(2R,5S)-5-methyl-4-propyl-2-morpholinyl]-2-pyridinamine (2:1), monohydrate (9CI) (CA INDEX NAME)

CM 1

CRN 710655-15-5
CMF C13 H21 N3 O

Absolute stereochemistry. Rotation (+).

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1288649 CAPLUS
DOCUMENT NUMBER: 144:36256
TITLE: Aminopyridine derivatives as selective dopamine D3 agonists, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Allerton, Charlotte Moira Norfor; Cook, Andrew Simon; Hepworth, David; Miller, Duncan Charles
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115985	A1	20051208	WO 2005-IB1554	20050517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247699	A1	20051208	AU 2005-247699	20050517
CA 2567935	AI	20051208	CA 2005-2567935	20050517
EP 1758862	A1	20070307	EP 2005-747191	20050517
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1956958	A	20070502	CN 2005-80017047	20050517
NL 1029139	A1	20051130	NL 2005-1029139	20050526
NL 1029139	C2	20060619		
US 2005288270	A1	20051229	US 2005-138708	20050526
NO 2006005326	A	20061219	NO 2006-5326	20061120
PRIORITY APPLN. INFO.:			GB 2004-11891 A	20040527
			GB 2004-12463 A	20040603
			US 2004-585133P P	20040701
			WO 2005-IB1554 W	20050517

OTHER SOURCE(S): MARPAT 144:36256
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to aminopyridine compds. of formula I, which are dopamine agonists, more particularly, agonists that are selective for D3

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
over D2. In compds. I, R1 and R2 are independently selected from H and C1-6 alkyl; and R3 is selected from (un)substituted morpholin-2-yl, (un)substituted thiomorpholin-2-yl, (un)substituted piperidin-3-yl, (un)substituted azetidin-3-yl, (un)substituted pyrrolidin-3-yl, and (un)substituted (di)alkylaminoethyl; including pharmaceutically acceptable salts, solvates, polymorphs, and prodrugs thereof. The invention also relates to the prepn. of I, pharmaceutical compns. comprising a compd. I and a pharmaceutically acceptable diluent or carrier, as well as to the use of the compns. for the treatment and/or prevention of sexual dysfunction. Condensation of 2-amino-5-bromopyridine with 2,5-hexanedione and coupling with 2-chloro-N-methoxy-N-methylacetamide gave pyridine II, which underwent asym. redn., ring closure to the epoxide, and ring opening with (S)-2-aminopropan-1-ol to give diol III. The pyrrole moiety of III was cleaved to release the free amine followed by morpholine ring closure, reductive amination with 3-phenylpropanal and HPLC sepn. of diastereomers to give compd. IV. The compds. of the invention are agonists of dopamine receptors and are selective for D3 over D2 (no data).
IT 870688-73-6P 870688-74-7P 870688-75-8P
870688-76-9P 870688-82-7P 870688-83-8P
870688-85-0P 870688-86-1P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chiral drug candidate; preparation of aminopyridine derivs. as selective dopamine D3 agonists)
RN 870688-73-6 CAPLUS
CN 3-Morpholinemethanol, 6-(6-amino-3-pyridinyl)-4-propyl-, (3S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-74-7 CAPLUS
CN 3-Morpholinemethanol, 6-(6-amino-3-pyridinyl)-4-propyl-, (3S,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 870688-75-8 CAPLUS
CN 3-Morpholinemethanol, 6-(6-amino-3-pyridinyl)-4-propyl-, (3R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-76-9 CAPLUS
CN 3-Morpholinemethanol, 6-(6-amino-3-pyridinyl)-4-propyl-, (3R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-82-7 CAPLUS
CN 2-Pyridinamine, 5-[(2S,5S)-4,5-diethyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 870688-83-8 CAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-4,5-diethyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-85-0 CAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-4-ethyl-5-methyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-86-1 CAPLUS
CN 2-Pyridinamine, 5-[(2S,5S)-4-ethyl-5-methyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 870688-65-6P 870688-66-7P 870688-67-8P
870688-68-9P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyridine derivs. as selective dopamine D3 agonists)
RN 870688-65-6 CAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-5-methyl-4-(3-phenylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-66-7 CAPLUS
CN 2-Pyridinamine, 5-[(2S,5S)-5-methyl-4-(3-phenylpropyl)-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-67-8 CAPLUS
CN 2-Pyridinamine, 5-[(2S,5S)-4-butyl-5-methyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-68-9 CAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-4-butyl-5-methyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



IT 870688-71-4P 870688-80-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyridine derivs. as selective dopamine D3 agonists)
RN 870688-71-4 CAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-5-[(phenylmethoxy)methyl]-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-80-5 CAPLUS
CN 2-Pyridinamine, 3-methyl-5-[(5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 870688-70-3P 870688-99-6P, (2R,5S)-2-(6-Aminopyridin-3-

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 870688-81-6P 870688-87-2P
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
PROC (Process); RACT (Reactant or reagent)
(racemic intermediate; preparation of aminopyridine derivs. as selective dopamine D3 agonists)
RN 870688-81-6 CAPLUS
CN 2-Pyridinamine, 5-[(5S)-4,5-diethyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-87-2 CAPLUS
CN 2-Pyridinamine, 5-[(5S)-4-ethyl-5-methyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
yl)-5-methylmorpholine-4-carboxylic acid benzyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of aminopyridine derivs. as selective dopamine D3 agonists)
RN 870688-70-3 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-(6-amino-3-pyridinyl)-5-[(phenylmethoxy)methyl]-, 1,1-dimethylethyl ester, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870688-99-6 CAPLUS
CN 4-Morpholinecarboxylic acid, 2-(6-amino-3-pyridinyl)-5-methyl-, phenylmethyl ester, (2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 870688-72-5P, [6-(6-Aminopyridin-3-yl)-4-propylmorpholin-3-yl]methanol
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(racemic intermediate; preparation of aminopyridine derivs. as selective dopamine D3 agonists)
RN 870688-72-5 CAPLUS
CN 3-Morpholinemethanol, 6-(6-amino-3-pyridinyl)-4-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:513545 CAPLUS
DOCUMENT NUMBER: 141:71567
TITLE: Preparation of 2-phenylmorpholines and related compounds as dopamine agonists in the treatment of sexual dysfunction.
INVENTOR(S): Allerton, Charlotte Maria Norfor; Baxter, Andrew Douglas; Cook, Andrew Simon; Hepworth, David; Wong, Stephen Kwok-fung
PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052372	A1	20040624	WO 2003-IB5683	20031202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508262	A1	20040624	CA 2003-2508262	20031202
AU 2003302878	A1	20040630	AU 2003-302878	20031202
US 2004259874	A1	20041223	US 2003-727168	20031202
EP 1572214	A1	20050914	EP 2003-812639	20031202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017102	A	20051025	BR 2003-17102	20031202
CN 1723023	A	20060118	CN 2003-80105677	20031202
JP 2006511599	T	20060406	JP 2005-502342	20031202
JP 3889775	B2	20070307		
NZ 540505	A	20070223	NZ 2003-540505	20031202
NL 1024983	A1	20040611	NL 2003-1024983	20031210
NL 1024983	C2	20050201		
IN 2005DN02094	A	20070105	IN 2005-DN2094	20050517
NO 2005002557	A	20050906	NO 2005-2557	20050526
JP 2006232857	A	20060907	JP 2006-157609	20060606
JP 3920908	B2	20070530		
US 2006235016	A1	20061019	US 2006-425030	20060619
JP 2007084575	A	20070405	JP 2006-352505	20061227
PRIORITY APPLN. INFO.:			GB 2002-28787 A	20021210
			GB 2003-8460 A	20030411
			GB 2003-13606 A	20030612
			US 2003-438476P P	20030107
			US 2003-470950P P	20030515

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

US 2003-501512P	P	20030908
JP 2005-502342	A3	20031202
US 2003-727168	A3	20031202
WO 2003-IB5683	W	20031202
JP 2006-157609	A3	20060606

OTHER SOURCE(S): MARPAT 141:71567

GI



I

II



III

AB Title compds. I [A = C-X, N; B = C-Y, N; R1 = H, alkyl; R2 = H, alkyl; X = H, OH, CONH2, etc.; Y = H, OH, NH2, etc.; Z = H, OH, F, etc.] their enantiomers and pharmaceutically acceptable salts were prepared For example, BH3-THF reduction of lactam II, e.g., prepared from 3-methoxybenzaldehyde in 5-steps, afforded 2-phenylmorpholine III in 84% yield. Compds. I expressed EC50 values < 1000 nM with 10-fold selectivity for D3 over D2, e.g., one example of compound I exhibited an EC50 value of 7.6 nM and 1315.8 fold selectivity for D3 over D2. Compds. I are claimed useful for the treatment of sexual dysfunction, e.g., hypoactive sexual activity, orgasmic disorders, erectile dysfunction, etc.

IT 710655-10-0P 710655-15-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 2-phenylmorpholines and related compds. as dopamine agonists in the treatment of sexual dysfunction.)

RN 710655-10-0 CAPLUS
CN 2-Pyridinamine, 5-[(2S,5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 710655-15-5 CAPLUS
CN 2-Pyridinamine, 5-[(2R,5S)-5-methyl-4-propyl-2-morpholinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



10/727,168> 07/11/2007

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.28	188.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

STN INTERNATIONAL LOGOFF AT 11:28:26 ON 11 JUL 2007